$215.01 Million in Sales Expected for American Renal Associates Holdings Inc (ARA) This Quarter

Wall Street brokerages expect American Renal Associates Holdings Inc (NYSE:ARA) to post sales of $215.01 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for American Renal Associates’ earnings, with the lowest sales estimate coming in at $210.84 million and the highest estimate coming in at $217.20 million. American Renal Associates reported sales of $194.38 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 10.6%. The company is expected to announce its next quarterly earnings report on Tuesday, March 5th.

On average, analysts expect that American Renal Associates will report full-year sales of $837.94 million for the current financial year, with estimates ranging from $833.71 million to $840.10 million. For the next financial year, analysts anticipate that the company will post sales of $891.20 million, with estimates ranging from $862.60 million to $910.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover American Renal Associates.

Several equities research analysts have weighed in on ARA shares. Morgan Stanley started coverage on American Renal Associates in a report on Friday, December 14th. They issued an “equal weight” rating for the company. SunTrust Banks reissued a “buy” rating and issued a $16.00 price target on shares of American Renal Associates in a report on Wednesday, January 9th. Zacks Investment Research raised American Renal Associates from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a report on Monday. Deutsche Bank started coverage on American Renal Associates in a report on Thursday, January 3rd. They issued a “hold” rating and a $12.00 price target for the company. Finally, Barclays started coverage on American Renal Associates in a report on Friday, December 14th. They issued an “equal weight” rating and a $18.00 price target for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $17.86.

Large investors have recently made changes to their positions in the company. MetLife Investment Advisors LLC purchased a new position in shares of American Renal Associates in the third quarter worth about $230,000. Squarepoint Ops LLC purchased a new position in shares of American Renal Associates in the fourth quarter worth about $125,000. Rhumbline Advisers raised its stake in shares of American Renal Associates by 47.5% in the fourth quarter. Rhumbline Advisers now owns 17,225 shares of the company’s stock worth $198,000 after purchasing an additional 5,549 shares during the last quarter. Engineers Gate Manager LP raised its stake in shares of American Renal Associates by 74.4% in the third quarter. Engineers Gate Manager LP now owns 22,892 shares of the company’s stock worth $496,000 after purchasing an additional 9,764 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. purchased a new position in shares of American Renal Associates in the third quarter worth about $559,000. Hedge funds and other institutional investors own 94.42% of the company’s stock.

NYSE ARA traded up $0.69 during trading on Friday, hitting $12.90. The company’s stock had a trading volume of 106,200 shares, compared to its average volume of 92,906. The company has a debt-to-equity ratio of 5.48, a quick ratio of 1.00 and a current ratio of 1.03. The company has a market cap of $387.28 million, a PE ratio of 21.15, a P/E/G ratio of 3.22 and a beta of 2.13. American Renal Associates has a fifty-two week low of $11.09 and a fifty-two week high of $24.07.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Further Reading: Why do companies issue stock splits?

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply